Clinical trials: Neovascular Age-related Macular Degeneration
- Condition Neovascular Age-related Macular Degeneration
- Funder type Industry (pharma, biotech, devices)
Neovascular Age-related Macular Degeneration
Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and efficacy of AS101 1% oral solution as compared to placebo in patients with neovascular Age-Related Macular Degeneration (AMD).
- Trial name
- NCT03216538
- Testing
- AS101 1% oral solution
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Feramda
Macular Degeneration
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
This is a Phase III, open-label, multicenter extension study of intravitreally administered ranibizumab in subjects with primary or recurrent subfoveal choroidal neovascularization (CNV) secondary to AMD who have completed the…
- Trial name
- NCT00095433
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- AQUARIUS (NCT07482176)
- Testing
- Ixo-vec, Aflibercept
- Where
- 79 sites in United States
- Volunteers
- 534 people
- Sponsor
- Adverum Biotechnologies, Inc.
Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.
- Trial name
- NCT01535950
- Testing
- LFG316
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related (Dry) Macular Degeneration
Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old.
- Trial name
- NCT07446582
- Testing
- Retina imaging device (MSI-120) and AI (DeepMSI AI)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- AI-Spectral
Age-related Macular Degeneration, Choroidal Neovascular Age-related Macular Degeneration
Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)
Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there…
- Trial name
- NCT01682382
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sequenom, Inc.
Neovascular (Wet) Age-related Macular Degeneration
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the…
- Trial name
- NCT06184360
- Where
- United States
- Volunteers
- 2,079 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular Age-Related Macular Degeneration.
- Trial name
- NCT04537884
- Testing
- UBX1325
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Unity Biotechnology, Inc.
nAMD
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.
- Trial name
- NCT06672536
- Testing
- SCT520FF, EYLEA 2 MG
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Sinocelltech Ltd.
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
- Trial name
- NCT07275840
- Testing
- IBI302 8mg dose
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Neovascular Age-Related Macular Degeneration (nAMD)
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
- Trial name
- NCT06116890
- Testing
- KHK4951, Aflibercept Injection
- Where
- 84 sites in United States, Australia and 2 more
- Volunteers
- 170 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Neovascular Age-Related Macular Degeneration
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
- Trial name
- ONYX (NCT02713204)
- Testing
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Where
- 87 sites in United States
- Volunteers
- 365 people
- Sponsor
- Regeneron Pharmaceuticals
Age-Related Macular Degeneration
Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
Palomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation.
- Trial name
- P52901 (NCT01033721)
- Testing
- Palomid 529
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Paloma Pharmaceuticals, Inc.
Neovascular Age Related Macular Degeneration
Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration
Age-related macular degeneration (AMD) is a disease that, in time, destroys the macula, which is the central part of the retina that gives sharp central vision.
- Trial name
- NCT00767949
- Testing
- iSONEP
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Lpath, Inc.
Neovascular (Wet) Age-Related Macular Degeneration
First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)
This is a first-in-human clinical trial evaluating the safety and tolerability of BETA-TT8 Ophthalmic Gel in people with wet age-related macular degeneration (AMD).
- Trial name
- BEyOND (NCT07766473)
- Testing
- BETA-TT8 ophthalmic gel 3.8% w/v
- Where
- 4 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Filamon LTD
Neovascular Age-related Macular Degeneration
Gene Therapy for Wet AMD
FT-003 is a gene therapy product developed for the treatment of neovascular age-related macular degeneration (nAMD). Neovascular AMD is the main cause of blindness among elderly individuals.
- Trial name
- NCT05611424
- Testing
- FT-003
- Volunteers
- 18 people
- Sponsor
- Frontera Therapeutics
Neovascular (Wet) AMD
Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)
This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
- Trial name
- NCT06550011
- Testing
- ABI-110 Low Dose, ABI-110 Medium Dose, ABI-110 High Dose
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Avirmax Biopharma Inc
Neovascular Age-related Macular Degeneration
A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).
In people with neovascular age-related macular degeneration (nAMD), the body makes too much of a protein called vascular endothelial growth factor (VEGF).
- Trial name
- BELUGA (NCT04641234)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Belgium
- Volunteers
- 330 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
This study is designed for multi-center, open-label, randomized, dose escalation phase I trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of IBI302 in neovascular AMD patients.
- Trial name
- NCT04370379
- Testing
- IBI302 (the first dose level), IBI302 (the second dose level), Aflibercept
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Trial name
- NCT06864988
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 94 sites in United States, Canada
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics